Suven Life Sciences Ltd. — Investor Relations & Filings
Suven Life Sciences Ltd. focuses on the discovery and development of novel therapeutic agents for Central Nervous System (CNS) disorders. The company specializes in New Chemical Entity (NCE) research, targeting unmet medical needs in conditions such as Alzheimer’s disease, schizophrenia, attention deficit hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s disease, and depression. Its clinical pipeline includes lead candidates like Masupirdine (SUVN-502) for cognitive impairment and Samelisant (SUVN-G3031) for narcolepsy. Suven utilizes an integrated drug discovery platform and maintains a significant global intellectual property portfolio. The organization provides drug discovery and development support services, leveraging expertise in medicinal chemistry and pharmacology to advance internal programs and collaborative research initiatives.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-04-23 | English | |
| Price movement | 2026-04-08 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English | |
| Outcome of Board Meeting | 2026-03-06 | English | |
| Allotment of Securities | 2026-03-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42171737 | Copy of Newspaper Publication | 2026-04-23 | English | ||
| 42187106 | Price movement | 2026-04-08 | English | ||
| 42208254 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42223422 | Trading Window | 2026-03-27 | English | ||
| 42197228 | Outcome of Board Meeting | 2026-03-06 | English | ||
| 42197303 | Allotment of Securities | 2026-03-06 | English | ||
| 42168398 | Copy of Newspaper Publication | 2026-02-19 | English | ||
| 42295958 | Price movement | 2026-02-06 | English | ||
| 42221508 | Monitoring Agency Report | 2026-02-03 | English | ||
| 42258219 | Copy of Newspaper Publication | 2026-01-30 | English | ||
| 42179002 | Appointment | 2026-01-29 | English | ||
| 42179326 | Resignation | 2026-01-29 | English | ||
| 42179815 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42180211 | Outcome of Board Meeting | 2026-01-29 | English | ||
| 42229887 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Alteogen Inc.
Biopharmaceutical firm developing biologics with proprietar…
|
196170 | KR | Professional, scientific and te… |
|
ALTERITY THERAPEUTICS LIMITED
Clinical-stage developer of disease-modifying therapies for…
|
ATH | AU | Professional, scientific and te… |
|
AlzeCure Pharma
Develops therapies for severe diseases, focusing on Alzheim…
|
ALZCUR | SE | Professional, scientific and te… |
|
AMPLIA THERAPEUTICS LIMITED
Clinical-stage developer of FAK inhibitors for solid tumors…
|
ATX | AU | Professional, scientific and te… |
|
ANAPTYSBIO, INC
Clinical-stage biotech developing immunology therapeutics f…
|
ANAB | US | Professional, scientific and te… |
|
ANATARA LIFESCIENCES LTD
Develops non-antibiotic gastrointestinal health solutions f…
|
ANR | AU | Professional, scientific and te… |
|
AngioLab, Inc.
Develops angiogenesis inhibitors for pharmaceuticals and he…
|
251280 | KR | Professional, scientific and te… |
|
Anhui Wanbang Pharmaceutical Technology Co.,Ltd.
Pharmaceutical CRO specializing in clinical trials, BE stud…
|
301520 | CN | Professional, scientific and te… |
|
Anixa Biosciences Inc
A clinical-stage biotech developing therapies and vaccines …
|
ANIX | US | Professional, scientific and te… |
|
Annovis Bio, Inc.
A clinical-stage drug platform company developing therapies…
|
ANVS | US | Professional, scientific and te… |
Suven Life Sciences Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61491/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61491 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61491 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61491 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61491}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Suven Life Sciences Ltd. (id: 61491)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.